- Conditions
- Cancer
- Interventions
- docetaxel, thalidomide
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 4,494
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer
- Interventions
- Stereotactic Body Radiotherapy
- Radiation
- Lead sponsor
- Crozer-Keystone Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Dexamethasone, Device for PET, Laboratory Biomarker Analysis, Positron Emission Tomography
- Drug · Device · Other + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms, Malignant Neoplasms
- Interventions
- PF-07284890, Binimetinib, Midazolam
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 39
- States / cities
- Duarte, California • San Francisco, California • Orlando, Florida + 23 more
- Conditions
- Lung Cancer
- Interventions
- cisplatin, gemcitabine hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Lung Cancer
- Interventions
- 18F-PEG6-IPQA, Positron emission tomography (PET)
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Interventions
- 6,8-Bis(benzylthio)octanoic Acid, Docetaxel, Pharmacological Study
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Cisplatin, Docetaxel, Laboratory Biomarker Analysis, Nintedanib
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- cisplatin, etoposide, conventional surgery, low-LET cobalt-60 gamma ray therapy
- Drug · Procedure · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2004
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Panobinostat, Cisplatin, Pemetrexed
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Sacramento, California • Detroit, Michigan
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Interventions
- amifostine trihydrate, cisplatin, etoposide, radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo
- Biological · Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2038
- U.S. locations
- 54
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 42 more
- Conditions
- Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Colon Cancer, Recurrent Malignant Mesothelioma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage III Colon Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Colon Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires
- Behavioral · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
- Interventions
- BAY2927088, Itraconazole, Carbamazepine
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer, Sarcoma, Renal Cell Carcinoma, Breast Cancer
- Interventions
- Fluciclatide Injection
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Capmatinib, Nazartinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- HomMed Telemonitor
- Device
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
- Interventions
- PF-06463922, Crizotinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 32
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Orange, California + 14 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- cisplatin, carboplatin, questionnaire administration
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Not listed
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Syracuse, New York • Winston-Salem, North Carolina
- Conditions
- Lung Cancer
- Interventions
- Biopsy of the major carinal area, Biopsy of abnormal & suspicious areas of the bronchial tree, Evaluation of the tumor for DNA mutations, Bronchoalveolar Lavage (BAL) for cytokine analysis, Correlation of flow cytometric & RT PCR for TNM stage, Analysis of lymph nodes
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2050
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced, Lymphoma, Metastatic Cancer, Non-Small Cell Lung Cancer, Sarcoma, Solid Tumors
- Interventions
- Modified FOLFOX6, Conatumumab, Ganitumab, Bevacizumab
- Drug · Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 10
- States / cities
- Duarte, California • La Jolla, California • Denver, Colorado + 7 more
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Pazopanib (GW786034)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Fort Myers, Florida • Orlando, Florida + 10 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 19
- States / cities
- Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more
- Conditions
- HER2-mutant Non-Small Cell Lung Cancer
- Interventions
- neratinib, temsirolimus
- Drug
- Lead sponsor
- Puma Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 15
- States / cities
- Duarte, California • Santa Monica, California • Aurora, Colorado + 10 more